Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 4/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2831852 | 0.83 | CNR1 (0.36) | KMT2ACNR2MEN1CNR1KDM4E | |
| SCHEMBL2832018 | 0.83 | KMT2A (0.39) | KMT2ANOTUMMEN1KDM4EPDE10A | |
| SCHEMBL1036361 | 0.81 | RORC (0.51) | RORCDHODHKMT2ANOTUMMEN1 | |
| SCHEMBL2832139 | 0.79 | CNR2 (0.55) | KMT2ACNR2MEN1CNR1 | |
| SCHEMBL2832896 | 0.79 | KDM4E (0.47) | KMT2AMEN1KDM4EPDE10A | |
| SCHEMBL2831445 | 0.78 | CNR2 (0.41) | RORCDHODHKMT2ANOTUMPBRM1 | |
| SCHEMBL2832957 | 0.78 | CNR2 (0.38) | RORCDHODHKMT2ACNR2MEN1 | |
| SCHEMBL2156061 | 0.77 | TACR3 (0.48) | KMT2AMEN1TP53 | |
| SCHEMBL2830806 | 0.76 | CNR2 (0.39) | RORCDHODHKMT2ANOTUMPBRM1 | |
| SCHEMBL2830203 | 0.76 | CNR2 (0.39) | RORCDHODHKMT2ACNR2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2342182-B1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | LUNDBECK & CO AS H (DK) | 2012-11-14 | — | — | EP | disclosed |
| US-8242134-B2 | Isoquinolinone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-08-14 | — | — | US | disclosed |
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-25 | — | — | US | disclosed |
| WO-2010028655-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2010-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076016-A1 | ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS | KCNQ3, KCNK3, GRIK3 | RORC 1235/4885DHODH 2224/4885KMT2A 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.